A trial looking at capecitabine after surgery for cancer of the bile duct or gallbladder (BILCAP)

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Bile duct cancer
Biliary tree cancers
Gallbladder cancer

Status:

Results

Phase:

Phase 3

This trial compared surgery and capecitabine with surgery alone for cancer of the bile duct or gallbladder (also called biliary tract cancer). 

Cancer Research UK supported this trial.

This trial was open for people to join between March 2006 and December 2014. The results were published in 2019.

More about this trial

For biliary tract cancer diagnosed at an early stage, the best treatment is an operation to remove it. But sometimes the cancer starts to grow again after surgery.

 Chemotherapy after surgery (adjuvant chemotherapy) can help stop some types of cancer from coming back. 

Doctors thought a chemotherapy drug called capecitabine (Xeloda) might stop biliary tract cancer coming back after surgery. But they weren’t sure. 

Capecitabine does have side effects, and it is important that people don’t have treatments they don’t need.

In this trial half the people had capecitabine after their surgery. And the other half didn’t have capecitabine.

The aim of this trial was to find out if capecitabine stopped cancer of the gall bladder or bile duct coming back after surgery.

 

Summary of results

The trial team found that taking capecitabine after surgery might lengthen the time people live. 
 
About this trial
This was a phase 3 trial
 
It was a randomised trial. Everyone who took part was put into 1 of 2 groups. Neither they nor their doctor chose which group they were in. 
 
447 people joined the trial. After their surgery:
  • 223 people had capecitabine
  • 224 people didn’t have capecitabine 

Results
The average follow up was 5 years. The team looked at the overall average length of time people lived after surgery. They found it was:
  • over 4 years (51.1 months) for those who had capecitabine
  • over 3 years (36.4 months) for those who didn’t have capecitabine

They also looked at the average length of time people were free of their cancer after surgery. They found it was:
  • just over 2 years (24.4 months) for those who had capecitabine
  • just under 1½ years (17.5 months) for those who didn’t have capecitabine

Long term follow up
The team compared the people who were to have treatment (intended to treat Open a glossary item) and those who actually had treatment. Looking at everyone who was randomised makes the results more accurate. This is so even if for some reason they didn’t have treatment.
 
Between years 2 and 5 after treatment they found that there was not much difference in how many people in each group were alive and had no sign of cancer. 
 
The researchers think it is because capecitabine might have delayed their cancer coming back. To understand this further the team is continuing to follow these people up. 
 
They will look at how many people are alive 5 years after their surgery. And will continue to follow everyone up for longer because it looks like capecitabine might delay the cancer coming back rather than stop it coming back. 
 
When these results are available we will update this summary. 
 
Side effects
In the capecitabine group 94 people (44%) reported having at least 1 severe side effect. The most commonly reported severe side effects were:
  • hand and foot syndrome 
  • diarrhoea
  • tiredness
Conclusion
The team concluded these results suggest that taking capecitabine after surgery to remove biliary tract cancer could improve the length of time people lived. So capecitabine after surgery should be considered as standard treatment Open a glossary item
 
Where this information comes from
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) and published in a medical journal. The figures we quote above were provided by the trial team who did the research. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor John Primrose

Supported by

Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
University of Southampton
Cancer Research UK Clinical Trials Unit, University of Birmingham

Other information

This is Cancer Research UK trial number CRUK/05/002.

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

481

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Charlie took part in a trial to try new treatments

A picture of Charlie

“I think it’s really important that people keep signing up to these type of trials to push research forward.”

Last reviewed:

Rate this page:

Currently rated: 5 out of 5 based on 1 vote
Thank you!
We've recently made some changes to the site, tell us what you think